NCT01359982 - Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Malignant Solid TumorLymphomas

Interventions

DRUG

RRx-001

Dose level 1 (10 mg/m2)

DRUG

RRx-001

Dose Level 2 (16.7 mg/m2)

DRUG

RRx-001

Dose Level 3 (24.6 mg/m2)

DRUG

RRx-001

Dose Level 4 (33 mg/m2)

DRUG

RRx-001

Dose Level 5 (55.0 mg/m2)

DRUG

RRx-001

Dose Level 6 (83 mg/m2)

Trial Locations (2)

Sarah Cannon Research Institute, Nashville

Moores University of California San Diego Cancer Center, La Jolla